Liquid Kaloba® (n = 31) | Liquid placebo (n = 26) | Tablet Kaloba® (n = 21) | Tablet placebo (n = 22) | All participants | |
---|---|---|---|---|---|
Last day of any moderately bad symptoms1 | 7 (4,15) | 12 (4,17) | 9 (5,13) | 9 (4,15) | 9 (4,14) |
First day of no moderately bad symptoms2 | 7 (4,8) | 8 (4,13) | 6.5 (4,11) | 8 (5,14.5) | 7 (4,11) |
Last day of any symptoms | 9 (6,17) | 13.5 (7,19) | 11 (8,14) | 12.5 (8,24) | 11 (7,17.5) |
First day of no symptoms | 10 (6,12) | 12 (6,17) | 7 (6,12) | 11 (8,15) | 9 (6,14) |
Moderately bad symptoms resolved by day 7? | 17/31 (54.8%) | 9/26 (34.6%) | 9/21 (42.9%) | 10/22 (45.5%) | 45/97 (46.4%) |
Moderately bad symptoms resolved by day 14? | 23/31 (74.2%) | 17/26 (65.4%) | 18/21 (85.7%) | 16/22 (72.7%) | 74/100 (74.0%) |
All symptoms resolved by day 7? | 10/31 (32.3%) | 7/26 (26.9%) | 4/21 (19.1%) | 5/22 (22.7%) | 26/100 (26.0%) |
All symptoms resolved by day 14? | 22/31 (71.0%) | 15/26 (57.7%) | 16/21 (76.2%) | 14/22 (63.6%) | 67/100 (67.0%) |
Antibiotics started? | 15/31 (48.4%) | 6/26 (23.1%) | 9/21 (47.6%) | 11/22 (50.0%) | 41/100 (41.0%) |
Days to first dose of antibiotics in those who reported taking them (median, interquartile range) | 1 (1,1) | 1 (1,8) | 1 (1,9) | 1 (1,6) | 1 (1,4) |